Celator’s New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer

The Life Sciences Report: Please give us an overview of your company, Celator Pharmaceuticals Inc. (CPXX:NASDAQ). Scott Jackson: Celator Pharmaceuticals is an oncology-focused biopharmaceutical company. Our mission is to improve and extend the lives . . . → Read More: Celator’s New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer Similar Articles: Stock Update (NYSE:BMY): Roche open to alliances in hunt for cancer drug combinations Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival Market Update (NASDAQ:ESRX): Express Scripts says AbbVie drug could displace Sovaldi on formulary